Extended-spectrum antibiotics for community-acquired pneumonia with a low risk for drug-resistant pathogens

Area of Science:

• Infectious Diseases
• Clinical Pharmacy
• Critical Care Medicine

Background:

• Extended-spectrum antibiotic use in community-acquired pneumonia (CAP) is common, but its necessity in low-risk patients is debated.
• Risk stratification for drug-resistant pathogens (DRPs) is vital for guiding empirical antibiotic therapy.
• The impact of unnecessary extended-spectrum antibiotic exposure on patient outcomes in low-risk CAP remains incompletely understood.

Purpose of the Study:

• To evaluate the association between unnecessary extended-spectrum antibiotic therapy and 30-day mortality in patients with CAP who are at low risk for DRPs.
• To determine if empirical antibiotic selection impacts outcomes in this specific patient population.

Main Methods:

• A post hoc analysis of a prospective multicenter observational study involving 750 CAP patients.
• Focus on 416 patients with low risk for DRPs, comparing outcomes between standard (n=257) and extended-spectrum (n=159) therapy groups.
• Multivariable logistic regression and propensity score analysis were employed to assess 30-day mortality and confirm findings.

Main Results:

• Extended-spectrum therapy was associated with significantly higher 30-day mortality (13.8%) compared to standard therapy (3.9%) in low-risk CAP patients.
• The adjusted odds ratio for 30-day mortality with extended-spectrum therapy was 2.82 (95% CI 1.20-6.66).
• Sensitivity analyses confirmed the robustness of these findings, indicating a consistent association.

Conclusions:

• Physicians should prioritize DRP risk assessment to avoid unnecessary extended-spectrum antibiotic administration in low-risk CAP patients.
• Judicious antibiotic selection, guided by risk stratification, is essential for improving patient outcomes and potentially reducing mortality.
• This study underscores the importance of de-escalating antibiotic therapy when appropriate.